ESR1 and breast carcinoma: Comprising 15–20% of all breast cancer cases [1], triple‐negative breast cancer (TNBC) is an aggressive subtype characterized by the lack of expression of estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor type 2 (HER2).